top of page

New 2026 Cholesterol Guidelines: ApoB and Lp(a) Explained

  • Writer: Sean Hashmi
    Sean Hashmi
  • 2 days ago
  • 3 min read

The short answer

In March 2026, the American College of Cardiology, the American Heart Association, and ten other organizations released a dyslipidemia guideline that retires the 2018 cholesterol rulebook, brings back hard LDL targets set by your risk, and moves two often-skipped numbers to the center. The first is ApoB, which counts the artery-damaging particles rather than the cholesterol they carry, so a normal LDL can still hide real risk in metabolic syndrome, prediabetes, or high triglycerides. The second is lipoprotein(a), or Lp(a), a mostly genetic particle that affects roughly one in five people, and the guideline now says every adult should measure it once. Lowering LDL still saves lives, and in clinic I regularly see someone relieved by a normal cholesterol whose particle count turns out high, so the practical move is to check whether ApoB and Lp(a) are even on your labs.


What we cover



Timestamps

00:00 What the 2026 guidelines changed

01:00 Why hard LDL targets are back

02:47 Are statins a scam? The evidence

04:44 Why your LDL target depends on your risk

06:17 ApoB, the particle count your panel skips

08:53 Lp(a), the one-time test every adult needs

12:10 Your one move this week


References

The 2026 ACC/AHA multisociety guideline on the management of dyslipidemia. A clinical practice guideline that replaces the 2018 blood cholesterol guideline, restores explicit LDL targets by risk, and formally addresses triglycerides and lipoprotein(a). Circulation, 2026. https://doi.org/10.1161/CIR.0000000000001423


The Cholesterol Treatment Trialists' meta-analysis pooled 170,000 people across 26 randomized trials and found each drop of about 39 mg/dL in LDL cut major vascular events by roughly a fifth, with benefit even when starting LDL was already low. Meta-analysis of randomized trials. Lancet, 2010. https://doi.org/10.1016/S0140-6736(10)61350-5


Glavinovic and colleagues laid out the physiology of why ApoB, the particle count, is a more accurate marker of cardiovascular risk than LDL cholesterol or non-HDL cholesterol. Physiology review. Journal of the American Heart Association, 2022. https://doi.org/10.1161/JAHA.122.025858


Solnica and colleagues measured ApoB, LDL, and non-HDL cholesterol in the NATPOL 2011 survey and found the two disagree often, with high-ApoB, low-LDL people carrying features of metabolic syndrome. Observational population survey, shows association, not causation. International Journal of Cardiology, 2023. https://doi.org/10.1016/j.ijcard.2023.131150


When to see a doctor

Ask your clinician to interpret your lipid panel and to add ApoB and a one-time Lp(a) if they are not already there, especially with metabolic syndrome, prediabetes, high triglycerides, chronic kidney disease, or a family history of early heart attacks.


Get my free metabolic health guides: https://guides.selfprinciple.org/metabolic


This content is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Hashmi's own and do not represent his employer.

 
 
 

Comments


bottom of page